Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
- Proposed 50:50 FlashDx joint venture adds a second GBS device
- StrepSure FDA submission target shifts to early 2027
- Hong Kong facility becomes Nexsen’s principal Asian R&D base
- New diagnostic programs target traumatic brain injury and neonatal sepsis
- $3.56 million cash balance and approximately four quarters of funding
Two-device GBS strategy takes shape
Nexsen Limited (ASX:NXN) is widening its route into Group B Streptococcus testing, but the trade-off is a later US regulatory milestone for its lead StrepSure device. The company said its proposed 50:50 joint venture with FlashDx Shenzhen would create a second molecular GBS test for hospitals and labour wards, while StrepSure remains aimed at antenatal screening and lower-resource clinical settings.
The FlashDx arrangement remains based on a non-binding term sheet, with definitive agreements still under negotiation. FlashDx brings an existing CE-marked, lab-grade molecular test that can produce a result in under an hour; Nexsen plans to add a sample-preparation step intended to improve sensitivity when bacterial levels are low. Nexsen is expected to lead commercial development across Asia-Pacific outside China and fund planned US FDA 510(k) and European CE-IVDR pathways. The proposed venture follows the earlier FlashDx JV proposal, which was described as a potential route into hospital and intrapartum testing.
StrepSure trial review delays FDA pathway
StrepSure’s current assessment has ceased after interim data from a Northern Health clinical study led to enrolment being suspended under the study protocol. Nexsen reported no adverse safety signal or event, but said the findings pointed to improvements needed in sensitivity and reliability before the device advances towards US submission.
The planned changes are intended to collect more GBS from each sample, replace visual interpretation with electronic reading and confirm results through two independent methods. Nexsen said the work builds on the existing design and is not expected to require material additional development expenditure. The US FDA submission target has consequently moved to early 2027, while the company continues development for antenatal screening and Asia-Pacific clinics. The shift builds on the StrepSure interim review, which had already identified performance enhancements before submission.
Hong Kong facility expands pipeline and regional reach
Nexsen has established a Hong Kong research and development facility as its principal Asian technical base, supported by a HK$6 million Ignite grant and relationships with four universities. The site is intended to support product development and clinical validation closer to regional researchers, clinicians, regulators and distribution partners, alongside Nexsen’s Australian operations and its research relationship with Universiti Malaya.
The facility is also supporting early programs in traumatic brain injury and neonatal sepsis, extending the pipeline beyond GBS and kidney diagnostics. These remain development programs rather than commercial products, and the announcement does not provide clinical performance data or regulatory timelines for either indication. Nexsen also appointed Professor Shekhar Kumta as executive director after quarter end, with responsibility for technical execution, while Reece O’Connell moved from executive chairman to non-executive chairman.
Cash runway leaves execution as the next test
Nexsen finished the September quarter with $3.561 million in cash after $851,000 of net operating outflows. Research and development and commercial activity accounted for $830,000 of quarterly expenditure, while the company received $134,000 in government grants and a $336,000 repayment from Universiti Malaya. On the reported operating cash-flow rate, the Appendix 4C indicates approximately four quarters of funding and no drawn financing facilities.
The runway provides room to progress the StrepSure upgrades, negotiate binding FlashDx documents and develop the Hong Kong-led programs, but it is not a substitute for regulatory or commercial validation. The immediate markers are whether the proposed joint venture becomes binding, whether the StrepSure enhancements produce a submission-ready device, and how quickly Nexsen can turn its expanded Asia-Pacific network into validated products.
Bottom Line?
Nexsen now has more diagnostic routes but also more execution points: binding the FlashDx venture, proving the StrepSure upgrades and managing cash through early 2027.
Questions in the middle?
- Will the non-binding FlashDx term sheet become definitive, and on what commercial and funding terms?
- Do the StrepSure enhancements resolve the performance issues identified in the interim clinical data?
- Can Nexsen advance its broader Asia-Pacific pipeline without materially lifting cash requirements before regulatory milestones?